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Abstract
Gene therapy is the use of genes to treat or prevent diseases. Diseases such as cancer, which are difficult to treat using
conventional methods, can be treated using gene therapy.The transport of the therapeutic transgene can be accomplished
using viral or non-viral methods. However, widespread use of viral vectors is limited due to its high cost of manufacture
and safety concern. Non-viral vectors are limited in their effectiveness.The use of transposons such as the Sleeping Beauty
transposon system can effectively deliver the transgene with less concern than viral vectors. This review discusses the
various vectors and treatment strategies using gene therapy to treat cancer.
Introduction
The molecular basis for cancer is now well understood to involve the genetic control of multiple genes that control cell cycle
and tissue growth. The random mutations that activate dominant
oncogenes or inactivate tumor suppression genes result in a cell
cloning itself with an abnormal pattern of growth control forming
a tumor. Traditional cancer therapies aim to destroy or remove
the tumor by chemotherapy, radiation or surgery. The problem
with both radiation and surgery is the ability of tumors to metastasize and spread cancerous cells to areas inaccessible to these
treatments or may not be noticeable at the time of treatment
allowing a secondary tumor to appear. The trouble with chemotherapy is its low therapeutic index for many cancers and the
rapid development of drug resistance in cancerous cells.
Gene therapy is a fundamentally different approach to the treatment of diseases. Originally proposed as treatment for inherited
autosomal recessive Mendelian disorders, such as hemophilia,
gene therapy is now being used to treat multiple acquired conditions including infections, degenerative diseases and cancer. Gene
therapy is the use of genetic material (genes) to express a specific
protein in a cell or to reduce the amount of protein by interfering
with its synthesis. Replacing a defective gene with a functional
one is the essence of gene therapy.
Cancer is widely believed to arise from mutations to the cell’s
DNA by either carcinogens or random mutations during cell
division. This genetic basis coupled with the limitations of the
traditional treatments, makes cancer a great candidate for gene
therapies. More than 60 percent of all gene targeted therapy clinical trials since 1989 aimed to treat cancer (Ginn et al, 2013).

Strategies for Gene Therapy for Cancer
Cancer is a disease that involves multiple genetic changes to oncogenes, tumor-suppressor genes and modifier genes. There is
also the intracellular interactions with multiple cells that regulate
the body’s immune response and the interaction with other cancer cells to maintain a solid tumor. Gene therapy can be used
alone or together with conventional treatments. It can be used
to sensitize cancerous cells to radiation or chemotherapy. It can
increase the body’s overall resistance to chemotherapy so larger
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doses can be used. Gene therapy can declump or shrink tumors
to allow for surgical removal. Various approaches are being examined both in preclinical studies and in clinical trials for gene
therapy for cancer.

Downregulation of Genetic Targets
To downregulate the expression of protein coded by oncogenes,
antisense molecules are used. Antisense molecules are synthetic oligodeoxynucliotides (ODN) that hybridize with the coding
(sense) mRNA of a specific gene. The antisense and sense molecules form double stranded RNA which cannot be translated
destroying the mRNA. ODNs are designed to be highly resistant
to nucleases which will destroy the mRNA (Stein et al., 1988). In
a phase I–II clinical study using antisense ODNs to target BCL2
(an anti-apoptotic oncogene) mRNA combined with chemotherapy in patients with advanced malignant melanomas, the antisense
ODN was found to successfully downregulate the target protein
and has shown anti-tumor effects in 6 of the 14 patients (Jansen
et al., 2000).

Immunomodulation by Gene Therapy
Because cancer cells originate from “self” cells, they generally do
not cause a strong immune response. However, the immune system can be augmented by gene therapy to increase their function.
Therapeutic genes can be introduced into tumor cells or into
effector cells such as T lymphocytes.
To elicit a greater immune response, tumor cells have been modified with the insertion of cytokine genes. Cytokines are small
cell signaling polypeptides involved in immunity and inflammation.
Systemic and local administration of cytokines from the interleukin (IL) family has shown significant reduction in tumor size but
have systemic side effects and short half-lives, making injection
of interleukins deficient in long term tumor control. However,
tumor cells modified to express IL-12 or IL-2 have shown the
same size reduction as well as long term remission and metastasis control (Gao et al., 2005, Tahara et al., 1995).
The receptors on T lymphocytes can be modified to target tumor-associated antigens.The most common method of creating an
artificial T cell receptor (TCR) is by protein fusion of single-chain
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variable fragments derived from monoclonal antibodies that
acts as the TCR ectodomain with the CD3-zetatransmembrane
and endodomain. The endodomain can be further modified
with co-stimulatory receptors to increase immunologic activity.
Leukemias from B cell linages are suitable targets for this therapy.
The CD19 antigen is expressed in differentiated cells with B cell
linages and is rarely lost in cancerous cells. Anti-CD19 T cells can
safely target and destroy cells expressing CD19 including cancerous cells, and they will later be replenished with healthy cells
(Scheuermann & Racila, 1995).
For effective activation of T cells, non-specific signals are needed
as well as the antigen-specific signal received by the T cell receptor. Co-stimulatory molecules interact with receptors, such as
CD28, on the T cell to provide the non-specific signals. Martinet
et al. (2000) has shown that transfection of both IL-12 and 4-1BB
ligand genes into tumor cells resulted in long-term remission
of liver metastases in mice. The 4-1BB ligand, a co-stimulatory
molecule that binds with the 4-1BB receptor on T cells, synergizes with the CD28 pathway to increase the immune response
(Melero et al., 1998).

‘Suicide’ Gene Therapy
A commonly used idea for gene treatment of solid tumors is
‘suicide’ gene therapy, where the cells expressing the therapeutic
gene are killed. Suicide genes code for enzymes that can activate a drug with an otherwise low toxicity. When suicide genes
are expressed only in the targeted cancer cells, the healthy cells
avoid the drugs toxic effect. One enzyme commonly used is herpes simplex thymidine kinase, which converts the nontoxic drug
Ganciclovir, into a toxic form by phosphorylation (Song et al.,
2009).The suicide gene can be placed under the control of tumor
specific promoters such as c-erbB2 in breast cancer, ensuring specific drug activation in the tumor (Pandha et al., 1999). Because
the enzyme can bleed into and kill neighboring non-transduced
cells in what is termed the bystander effect, suicide genes can
be optimized to only require ten percent transduction in a solid
tumor greatly increasing its efficiency (Xiong et al., 2012).
Apoptosis-inducing genes One of the problems involved in treating solid tumors by conventional therapies is that cancerous cells
are often resistant to apoptosis and will not die with chemotherapy or radiation therapy alone. The gene that codes for the
anti-tumor protein p53 is either mutated or deleted in more than
50 percent of human tumors (Hollstein et al, 1991). Inserting a
copy of wild type p53 into cancerous cells has been shown to
induce apoptosis and make the cells more susceptible to chemotherapy and radiation therapy.

Anti-angiogenesis
Tumors, just like any tissue, require a constant supply of nutrients,
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oxygen, hormones and growth factors for their growth and progression. This is provided by the formation of new blood vessels or angiogenesis. Therefore, inhibition of angiogenesis would
stunt tumor growth. Patients with glioblastoma multiforme, a
highly vascularized form of brain cancer that does not respond
well to conventional treatments, would benefit greatly from an
anti-angiogenic treatment. Even poorly vascularized tumors can
be reduced by anti-angiogenic treatment (Beecken et al., 2001).
Clinical trials involving systemic administration of angiogenic inhibitors such as angiostatin and endostatin showed no dose-limiting toxicity. However, they did not show marked signs of tumor
regression due to the continuous release of pro-angiogenic
factors released by the tumor (Ohlfest et al., 2005, Shepherd &
Sridhar, 2003). Therefore, the delivery of angiogenic inhibitors by
gene transfer is favored over systemic administration.

Gene Transfer Techniques
The success of gene therapy lies in the efficient delivery of the
gene of interest to the target cell. The therapeutic gene is cloned
into a vector together with appropriate regulatory regions (promoters/enhancers) as well as any supporting proteins needed.
Selecting the right vector is a crucial part of gene therapy. The
ideal vector will protect and easily deliver the genetic information across the cell membrane and into the nucleus. It should
have the ability to regulate the expression of the gene of interest
and be able to successfully target specific cells to minimize toxicity. It should be easy and inexpensive to produce in large quantities. Once the gene is cloned into the vector it can be introduced
to the target cell. The gene can be delivered in vitro or in vivo.
In in vitro transfer, cells from a specific tissue are removed from
the patient and exposed to the gene-carrying vector. The transformed cells are selected by biomarkers and are reintroduced
into the patient’s body. In in vivo transfer, the vector is injected
into the patient’s body directly, usually into the target tissue or
the tumor if a tumor is the target.

Viral Vectors
Currently, the most effective method of gene transfer is though
viral vectors.Viruses have evolved over the years to enter the cell
and efficiently hijack the cell’s machinery to produce its own viral
proteins. An ideal viral vector uses the viral infection pathway but
avoids the expression of the viral genes that facilitate replication
and the subsequent host cell death. This is achieved by deleting
most of the viral genome, leaving intact the sequences (usually
the long terminal repeats) required for capsid packaging and integration of the vector DNA into the host’s chromatin.The most
commonly used viruses for gene therapy are retrovirus, lentivirus
and adenovirus.
Retroviruses carry their genetic material as RNA and integrate
their genome into host DNA using the viral enzymes reverse
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transcriptase and integrase. The integrated DNA acts as a provirus which replicates to make multiple copies of the virus and
is released outside the cell. Therapeutic retroviral vectors are
made replication-deficient by replacing the structural genes with
the therapeutic gene. Since retroviruses only gain access to the
host’s DNA when the nuclear membrane is broken down, they
only infect actively dividing cells and integrate the gene of interest
into the target cell.
Lentiviruses, a subclass of retroviruses, have recently been adapted to be used as gene transmission vectors. Lentivirus vectors
can naturally enter an intact nuclear membrane and integrate
their genome into non-dividing cells, which a retrovirus vector
cannot do. HIV-1 is the most common lentivirus used in gene
transfer. Because of its dangerous nature, lentivirus vectors do
not carry the gene required for replication. As an added precaution, self-inactivating (SIN) lentivirus vectors are being developed
which contain deletions in the downstream LTR.
Adenoviruses carry their genetic material as double stranded
DNA, but as opposed to the other viruses mentioned, the DNA
is not integrated into the host’s genome. However, adenovirus
can successfully infect broad range of cell type and is not limited
to dividing cells. In 2003 the first gene therapy to be approved for
commercial production was a recombinant adenovirus-p53 gene
therapy for head and neck squamous cell carcinoma approved by
China’s State Food and Drug Administration and is sold under
the name Gendicine (Pearson et al., 2004).

disease developed a form of leukemia. The cause in at least two
of the patients appeared to be the integration of the therapeutic
murine leukemia virus retroviral vector close to the LMO2 oncogene (Kohn et al., 2003).
Adenovirus vectors, since they do not integrate the gene into the
host’s genome, carry no risk of insertional mutagenesis. However,
since adenovirus vectors to not integrate the gene into the cell’s
DNA they are only expressed transiently and require multiple
administrations to be effective and repeated delivery may compromise efficacy and might induce a severe immune response
(Hartman et al, 2008).
While self-inactivating (SIN) retroviral vectors may reduce the
risk of insertional mutagenesis (Ellis, 2005), the clinical use of retroviral vectors is curtailed due the limited packaging capacity of
viral vectors. Most retroviral vectors can carry a transgene of up
to 8 kb, as larger genes would compromise the efficiency of viral
reverse transcription (Thomas et al,. 2003). This excludes the
transport of multiple or large transgenes. Finally, the high costs
involved in the manufacture of clinical-grade retroviral vector and
regulatory issues keep viral vectors from widespread translation
into clinical practice.

Non-viral Methods
The simplest method of gene delivery is injecting naked DNA
directly into the target tissue. Since naked DNA lacks any mode
of transport through the cell membrane, there have been various
methods developed to increase the efficiency of cellular uptake.

Limitations of Viral Vectors
The obvious concern regarding the use of viral vectors is the
possibility of the virus eliciting a strong immune response. In
1999, an 18-year-old male died due to an extreme immune response triggered by the administration of an adenoviral vector.
He was participating in a phase I clinical trial to determine the
safety of a gene therapy for ornithine transcarbamylase deficiency, an X-linked genetic disease of the liver (Raper et al., 2003).
Since then most work with adenovirus vectors used genetically
crippled constructs which would minimize the likelihood of an
immune response.
The integration of the therapeutic gene when using retroviral
or lentiviral vectors carries a possibility of oncogene activation.
Since the point of insertion is mostly random, the transgene can
insert into the upstream regulatory region of an existing gene
and activate or upregulate the existing gene due to the proximity
to the promoters in the downstream LTR of the transgene. The
transgene can also insert itself into a transcriptional unit of an
existing gene causing a loss of function in that gene. This was
shown to be a real threat when four patients in a clinical trial that
successfully treated X-linked severe combined immunodeficiency

In smaller animals, hydrodynamic injection can overcome the low
efficiency of cellular uptake.This procedure involves the injection
of a large volume, about 10% the weight of the mouse, of DNA/
saline solution through the tail vein in less than 10 seconds, with
most of the protein being expressed and accumulating in the liver
(Liu et al., 1999). In larger animals, the volumes required for hydrodynamic injection become prohibitive. This limitation can be
overcome by isolating an organ’s blood flow using catheters or
part of a limb using external tourniquets.
The efficiency of delivery can be enhanced by physical methods
such as microinjection directly into the cell, electroporation, sonoporation and the use of microparticle in gene guns and magnetofection. Most of these methods are only feasible in in vitro
gene delivery. Electroporation has been used successfully in gene
delivery to mice skeletal muscle in vivo (Miyazaki et al., 2002), but
the larger energy required to increase the permeability of the
cell membrane across a human limb risks destroying too many
cells. Sonoporation is limited to acoustically accessible organs.
Although these methods are efficient, they require expensive
specialized equipment reducing their benefit over viral vectors.
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The efficiency of delivery can also be increased by chemical
methods. The negatively charged phosphate on DNA can bind
to a variety of cationic polymers to form a DNA-polymer complex called a polyplex. The polyplex interacts with the cell membrane and is absorbed into the cell by phagocytosis where the
polyplex is released and the DNA can migrate into the nucleus.
Polyethylenimine (PEI) is one of the most commonly used non-viral vectors based on polycations for DNA delivery both in vitro
and in vivo. PEI is a polymer with repeating units composed of an
amine group and two carbon spacers. PEI can be linear, branched
or as a highly branched dendrimer, though linear PEI is more
commonly used. The exact mechanism my which the DNA-PEI
polyplex escapes the endosome is unknown but is thought to
be a result of the increased influx of protons, chloride ions, and
water during endosome acidification causing it to rupture from
the high osmotic pressure. Using confocal laser scanning microscopy, Merdan et al. (2002) observed the dispersal of the genetic
cargo soon after the rupture of the endosomes on living cells.
Cationic lipids are also used to condense the DNA into a liposome.These liposomes can protect the DNA from damage during
transport, something that the other non-viral delivery methods
fail to do. Suzuki et al. (2010) successfully transfected murine
ovarian tumors in vivo with IL-12 using self-prepared bubble liposomes combined with ultrasound applied to the tumor. The bubble liposome protocol was more effective than using the more
expense commercially available transfection agent, Lipofectamine
2000. However, the Lipofectamine control in the study was not
conducted together with ultrasound.
Non-viral methods present many advantages over viral vectors.
Most non-viral methods are simpler and cheaper to produce
and elicit a smaller host immune response. The transfer capacity of non-viral methods is functionally unlimited compared to
viral capacity. Low levels of transfection used to be the limiting
disadvantage, but advances have resulted in methods with transfection rates that are clinically viable and can compete with viral
vectors. However, the efficient delivery of DNA to the nucleus is
not enough for long-term transgene expression if it cannot integrate into the host genome.Transposable elements (transposons)
could potentially offer such an alternative.

Transposon Systems for Gene Therapy
Transposons or transposable elements (TE) are mobile regions
of DNA that can change their position in the genome. DNA
transposons rely on a transposase enzyme to cut the TE from
the donor site and insert it at the receiving site in a ‘cut-andpaste’ like manner. The transposase gene is the trans-acting element of the transposon system. The cis-acting element is a pair
of inverted repeats at either end of the gene which are the target
sites for the transposase as well as associated enhancers and
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promoters. Most regions coding for transposase also contain the
cis-acting elements and are considered autonomous TEs. While
transposons seem to have played a large role in evolution with
close to fifty percent of the human genome made up of TEs, most
species have accumulated mutations in the transposase genes.
One family of transposons, the mariner/tc1-like superfamily, has
members in a wide range of species including nematodes, insects,
fish, and humans with analogs reported in prokaryotes. This is a
result of horizontal gene transfer between species. Unfortunately,
not a single autonomous element has been isolated from vertebrates. Ivics et al. (1997) reconstructed the first man-made transposon system called the Sleeping Beauty (SB) transposon system
based on the consensus sequence of members of the mariner/tc1
family isolated from fish. The reconstructed SB transposase was
successfully able to transfer elements not only in fish but also in
other species including human cells. The use of a SB transposon
based system of gene transfer was proposed in 2000 when successful integration and long tern expression using SB was shown
in mice (Yant et al., 2000).
Because transposons have to survive along with the host cell,
traits that posed less of a threat to the cell were selected evolutionarily. A transposase with a high activity increases the chance
of insertional mutagenesis. Therefore, early iterations of the SB
tranposase had lower activity that could not compete with the
fast acting retroviral enzymes. It was known early on that exchanging certain amino acids in SB transposase could increase its
efficiency, but guessing the right combination of changes needed
to construct a hyperactive transposase would be near impossible.
Mates et al. (2009) conducted a large scale genetic screen of SB
mutants and yielded a transposase (SB100X) that was ~100 times
more efficient than first generation SB transposases. This hyperactive transposase allows the SB transposon system to compete
with viral vectors and was awarded the title of “Molecule of the
Year, 2009. ”
Since SB transposon based vectors integrate the transgene into
the host’s DNA, just as retroviral and lentiviral vectors do, they
also pose the risk of insertional mutagenesis. Statistical analysis
of the integration sites of both viral integrase and SB transposase
suggests the SB vectors are safer. SB transposons integrate at
TA dinucleotides and shows a preference (p<0.01) for a short
TA palindromic consensus sequence. This preference can be
explained by the greater bendability at TA sites that is possibly
required to allow the transposase access, but with ~108 TA sites
in the human genome this can still be considered random on a
genomic level. A study mapping over 1,300 SB integration sites
found 39 percent (p=0.02) integrated into known genes with a
weak preference for regions slightly upstream or within 5kb of
the start site (Yant et al., 2005). These results were compared to
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10,000 computer-simulated insertions that showed truly random
insertions would only result in 33 percent of genes. It is hard
to avoid any preference for transcriptionally active genes since
those are accessible due to chromatin modification such CpG
islands. Even though SB transposon shows a statistically significant preference for genes, the percentages are low compared to
viral vector insertions. Schröder et al. (2002) reported 69 percent (p<0.0001) of in vivo integration sites using HIV-1 vectors
were in known genes. Adding insulator sequences to the ends of
transposable element can further reduce the risk of unwanted
activation of neighboring genes (Walisko et al., 2007).
Long term expression of the transposase gene can result in the
transposon being excised and reinserted in a different location in
what is known as “re-hopping”, increasing the risk of insertional
mutagenesis. To limit the amount of time in which transposase
will be produced the transposase gene can transported on a second plasmid that will be transcribed ectopically and destroyed.
The use of mRNA as a source of transposase in also being explored (Wilber et al., 2006).
The greatest weakness of the SB transposon system is its inability
to infect cells. Any of the non-viral delivery methods mentioned
above can be used to transport the SB-containing plasmid. There
is also the possibility of using hybrid vectors that transport the
transposon packaged into virions.These hybrid vectors may prove
more effective than either method alone. The integration sites
of an HIV-1/SB hybrid was shown to be closer to truly random
integration profile with only 30 percent inserting into known
genes (Staunstrup et al., 2009), and a herpes simplex virus/SB hybrid has successfully increased the capacity of the SB transposon
(de Silva et al., 2009). SB transposon have also been successfully
delivered to target tissue using modified liposomes that used
Asialoglycoprotein receptor (ASGPR)-mediated endocytosis to
target hepatocytes in vivo (Wang et al., 2009) and hybrid vectors
may be employ similar targeting techniques being researched for
viral vectors (Waehler et al., 2007).
Since transposons simply ‘cut-and-paste’, they do not have to rely
on reverse transcriptase which has a tendency to incorporate
mutations.The transposase can possibly be modified in the future
to target a specific region of DNA using a synthetic zinc finger
domain (Yant et al., 2007). SB transposons are easier and cheaper
to manufacture than replication-incompetent viral vectors, allowing researchers without the resources required to produce viral
vectors to continue exploring transposon based systems.

and resultant bureaucracy has limited the widespread use of
commercially licensed gene therapy treatments. There are only
two approved gene therapies worldwide in over 25 years of
clinical trials, mostly due to safety and toxicity concern and not
effectiveness. There is a need for a safer delivery system and the
SB transposon system may be it. Most of its early limitations have
been resolved to the point that it can compete with viral vectors.
SB-mediated gene transfer has been shown to be effective in a variety of treatment strategies including anti-angiogenesis (Ohlfest
et al., 2005), suicide therapy (Song et al., 2009), and others.
The first human clinical trial using SB transposons is under way.
The trial will attempt to transfect T cells ex vivo with engineered
receptors against the CD19 antigen as described above (Williams,
2008). Regardless of what the results of this trial will be in terms
of efficacy, the trial will prove the safety of this method and provide the data necessary for further improvement in future trials.
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